查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095294

生物製藥契約製造市場－全球市場預測（2026-2032年）

Biopharmaceuticals Contract Manufacturing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製藥契約製造市場將成長至 1,241.1 億美元，複合年成長率為 11.41%。

主要市場統計數據
基準年 2025 582.5億美元
預計年份：2026年 646.8億美元
預測年份 2032 1241.1億美元
複合年成長率 (%) 11.41%

生物製藥契約製造已成為製藥研發公司尋求可擴展生產能力、專業技術專長以及生技藥品、疫苗、生物類似藥、細胞療法、基因療法和先進蛋白藥物監管合規性的戰略支柱。隨著生技藥品研發管線的擴展和產品模式的日益複雜，外包合作夥伴的參與度越來越高，其服務範圍涵蓋細胞株開發、製程最佳化、臨床供應、商業化生產、灌裝和包裝、分析測試以及監管合規支援等各個環節。該領域的發展受到嚴格的現行藥品生產品質管理規範 (cGMP) 要求、一次性生物製程的日益普及、對品質源於設計 (QbD) 的更高期望以及對具有韌性的全球供應鏈的需求等因素的影響。監管機構和公共衛生部門提出的要求最終都歸結為以下幾個基本要素：經過驗證的流程、完善的污染控制、可追溯的原料、可靠的低溫運輸管理以及可測試的品管系統。對於行業領導者而言，競爭優勢現在取決於靈活的製造網路、數位化流程控制、快速的技術轉移，以及在不損害品質、可追溯性或監管應對力的前提下，支持大批量生技藥品和小批量個性化療法的能力。

一項變革性的變革，將徹底改變外包產業的格局。

隨著需求從傳統生物製藥轉向更多樣化、技術更先進的療法，生物製藥契約製造行業正在經歷結構性變革。製造商正在拓展其在哺乳動物細胞培養、微生物發酵、高活性生物製藥處理、病毒載體生產、mRNA相關工作流程、無菌填充和包裝以及低溫運輸配送方面的能力。一次性系統縮短了換線時間，降低了交叉污染的風險，而模組化設施則提高了對臨床和商業專案的應對力。監管機構持續強調資料完整性、製程驗證、環境監測、無菌保證和供應鏈透明度，要求契約製造製造商加強數位化品質系統和端到端文件記錄。同時，地緣政治的不確定性、疫情期間的經驗教訓、藥品安全政策以及區域生物製造激勵措施正在推動近岸外包、雙重採購和在地化生產策略的出現。因此，一個更加分散、技術密集的外包生態系統正在興起，在這個生態系統中，速度、合規性、柔軟性、科學專業知識以及生產能力至關重要。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過提升製程理解、營運效率、品質監控和決策能力，對生物製藥契約製造日益顯著的影響。 AI 驅動的分析，結合檢驗的資料管治框架，可以支援細胞培養最佳化、培養基配方評估、偏差檢測、預測性維護、批次效能建模以及即時產品放行策略。機器學習工具也有助於分析大量數據，例如製程分析技術 (PAT) 數據、環境監測記錄和品管結果，從而識別傳統審核中可能被忽略的模式。在生產營運中，AI 可以協助最佳化排程、生產力計畫、原料風險評估以及文件工作流程的自動化。然而，其應用必須符合有關驗證、可解釋性、網路安全、審計追蹤和人工監督的監管要求。這包括國際良好生產規範 (GMP) 和電腦化系統指南中所體現的原則。人工智慧的整體影響不是取代科學和品質方面的專業知識，而是增強製程控制、加快根本原因分析、減少操作變異性，並增強應對日益複雜的生技藥品生產模式的應對力。

生物製藥契約製造的區域趨勢

亞太地區正透過擴大生物製藥基礎設施、政府對本地藥品生產的支持以及在中國、印度、日本、韓國、澳洲和東南亞等地加強臨床研發力度，不斷提升其在生物製藥契約製造的地位。該地區擁有豐富的技術人才儲備、日益完善的監管體系，以及對生物相似藥、疫苗、細胞療法、無菌生產和技術轉移的持續投資。歐洲憑藉著成熟的法律規範體系、專業的技術人才以及歐盟主要國家和英國在無菌生產、生物相似藥、疫苗和先進療法方面的強大實力，仍然是高品質生物製藥生產的領先英國。北美，尤其是美國和加拿大，憑藉其先進的生物製藥創新基礎、完善的法規結構、強大的臨床研發管線以及對高度合規的商業化生物製藥生產的需求，仍然是至關重要的中心。拉丁美洲正逐步取得進展，各國政府和醫療衛生系統優先考慮疫苗安全、本地生物製藥供應和技術轉讓，巴西和墨西哥在區域製藥生產中發揮核心作用。非洲尚處於起步階段，但其在疫苗生產方面的優先地位、確保公共衛生安全的目標以及加強區域藥品自給自足的努力正引起政策制定者的關注，為人力資源開發、監管能力建設和合規的本地生產創造了長期機遇。在中東，隨著醫療保健多元化、生命科學產業發展以及對區域供應韌性的需求，生物製藥的重要性日益凸顯。尤其是在海灣國家，本地藥品生產和醫院系統現代化正成為戰略重點。

針對特定族群的製造策略關鍵見解

儘管北約成員國並非商業集團，但它們在供應鏈韌性、生物安全準備和醫療基礎設施協調方面構成了一個具有重要戰略意義的網路，這促使人們對安全可靠的生產能力、冗餘來源以及關鍵生物製藥的可靠獲取途徑日益關注。七國集團（G7）憑藉其強大的創新生態系統、嚴格的品質標準、先進的監管機構以及先鋒生物製藥、疫苗和先進療法研發的集中，仍然是高價值契約製造需求的中心。金磚國家（BRICS）憑藉其大規模的患者群體、不斷壯大的國內製藥產業、日益豐富的生物製藥研發管線以及對本地生產、生物相似藥和技術轉移的政策支持，在全球生產韌性方面發揮著核心作用。歐盟（EU）憑藉其統一的監管體系、健全的藥品安全監測框架、高技能的生物製造人才以及對生物類似藥、無菌生物製藥和先進療法的穩定需求，仍然具有舉足輕重的影響力。隨著東協成員國擴大醫療保健服務覆蓋範圍、吸引醫藥投資並加強生物製藥和疫苗領域的監管合作，海灣合作理事會（GCC）正崛起為生物製藥契約製造的重要力量。 GCC將生命科學領域的本土化作為其更廣泛經濟多元化策略的優先事項，重點關注藥品安全、醫院需求、低溫運輸基礎設施和戰略製造夥伴關係。

主要國家的市場洞察

由於國內創新、監管現代化以及對研發和生產外包服務日益成長的需求，中國正迅速擴大其生技藥品和細胞療法的生產能力。美國憑藉其豐富的生技藥品研發管線、先進的法規環境以及集中的臨床和商業藥物研發，正引領先進生物製藥契約製造的需求。日本在高品質生物製藥生產、嚴格的管理體制和專科治療領域持續展現優勢，而印度則在生物相似藥、疫苗、製程開發和具成本效益藥物生產方面處於領先地位，並日益重視全球品質標準。德國以其高品質的製藥工程、自動化、無菌製程和生物製藥生產能力而備受推崇，而英國則在先進治療、生物製藥研究、臨床生產專業知識和轉化科學基礎設施方面繼續發揮重要作用。澳洲支持臨床生物製造、早期研發和區域研究合作，而法國則憑藉其強大的疫苗、無菌生產和生命科學基礎設施做出貢獻。韓國已成為亞太地區領先的生物製藥中心，在大規模生物製藥生產、生物相似藥和先進的設施管理方面擁有雄厚的實力。義大利和西班牙在歐洲的無菌生產、填充和包裝以及製藥服務領域都扮演著重要角色。加拿大透過投資生技藥品、疫苗生產能力和生命科學創新來支持生物製藥生態系統的發展，而俄羅斯的生物製藥生產格局則受到國內供應優先事項和本地化政策的影響。巴西仍然是拉丁美洲最重要的生技藥品生產市場，這得益於公共衛生計畫、技術轉移舉措以及對生物相似藥的關注。墨西哥作為近岸外包目的地，其重要性日益凸顯，為製藥供應鏈、包裝以及滿足區域醫療保健需求提供支援。

為行業領導者提供的實用建議

產業領導者應將生產柔軟性、監管準備和供應鏈韌性作為核心策略挑戰優先考慮。契約製造組織 (CMO) 和生物製藥申辦者應投資於模組化生產能力、一次性技術、先進分析、檢驗的數位化品質系統和穩健的污染控制策略。技術轉移應被視為一個嚴謹的、數據驅動的過程，並以標準化文件、明確的程式參數、分析方法的可比性以及研發團隊和生產團隊之間的早期協作為支撐。領導者也應實現關鍵原料來源多元化，核實二級供應商的合格，並加強對敏感生技藥品和先進療法的低溫運輸和無菌物流規劃。程式工程、品質保證、法規事務、分析測試和先進療法生產方面。在評估策略夥伴關係關係時，不僅要考慮成本，還要考慮技術能力、檢查應對力、品質文化、擴充性、生命週期支援以及將專案從臨床批次過渡到商業供應的能力。

基於證據的洞見的調查方法

本執行摘要採用系統性的二手研究途徑編寫，重點在於檢驗的產業、監管、科學和公共政策資訊來源。該調查方法強調對來自監管指南、公共衛生機構出版刊物、同行評審的科學文獻、臨床開發趨勢、生產技術文件、貿易政策更新以及與生技藥品和藥品生產相關的官方政府舉措的資訊進行三角驗證。透過對多個可靠資訊來源進行定性檢驗，評估了相關見解，以檢驗技術採用、區域生產發展、監管預期、外包策略和供應鏈優先事項方面的一致模式。特別關注良好生產規範 (GMP) 要求、資料完整性原則、生技藥品品質指南、無菌生產預期、疫苗安全措施以及先進治療藥物生產的考慮因素。為確保以證據為基礎的策略解讀，本分析未包含市場規模估算、收入預測、市佔率計算和未來預測。在本研究框架內，優先考慮資料完整性、資訊來源可靠性、當前監管相關性以及對參與生物製藥契約製造的相關人員的可操作性。

結論：契約製造的策略展望

生物製藥契約製造正從單純的生產能力外包模式轉向以科學專長、卓越的監管能力、數位化成熟度和全球供應鏈韌性為特徵的策略夥伴關係模式。隨著生物製藥模式的多樣化和生產要求的日益複雜，成功的關鍵在於能否將靈活的生產平台與嚴格的品質系統、檢驗的數位化工具和快速的技術轉移相結合。在地化、人工智慧驅動的流程智慧、一次性生物程序、先進的治療藥物生產以及更強大的供應保障正在重塑申辦方選擇合作夥伴的方式以及製造商設計面向未來的業務運營模式。那些投資於合規創新、技能人才、強大的供應商網路、透明的品質管治以及隨時準備接受檢查的運營執行的企業，將更有能力支持下一代生技藥品、生物類似藥、疫苗和個人化醫療的發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物製藥契約製造市場：依服務類型分類

  • 分析和品管測試
  • 生物製藥生產服務
  • 製程開發與最佳化

第8章：生物製藥契約製造市場：依產品類型分類

  • 細胞和基因治療
    • CAR-T療法
    • 基因編輯療法
  • 單株抗體
  • 重組蛋白
    • 酵素
    • 荷爾蒙
  • 疫苗
    • 藥效疫苗
    • 蛋白質次單元疫苗
    • 病毒載體疫苗

第9章：生物製藥契約製造市場：依生產階段分類

  • 臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業

第10章：生物製藥契約製造市場：依組織規模分類

  • 大型組織
  • 中小企業

第11章：生物製藥契約製造市場：依應用領域分類

  • 自體免疫疾病
  • 心血管疾病
  • 感染疾病
    • 細菌
    • 寄生蟲病
    • 病毒性的
  • 神經病學
  • 腫瘤學

第12章：生物製藥契約製造市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：生物製藥契約製造市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：生物製藥契約製造市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Aenova Holding GmbH
  • AGC Biologics
  • Ajinomoto Co., Inc.
  • Binex Co., Ltd.
  • BioVectra Inc.
  • Boehringer Ingelheim International GmbH
  • BSP Pharmaceuticals SpA
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Cytovance Biologics, Inc.
  • Emergent BioSolutions Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • GenScript Biotech Corporation
  • IDT Biologika GmbH
  • Jubilant Pharmova Limited
  • KBI Biopharma, Inc.
  • Lonza Group AG
  • Piramal Pharma Limited
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • ST Pharm Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • ThermoGenesis Holdings, Inc.
Product Code: MRR-8C74ADFC15ED

The Biopharmaceuticals Contract Manufacturing Market is projected to grow by USD 124.11 billion at a CAGR of 11.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 58.25 billion
Estimated Year [2026] USD 64.68 billion
Forecast Year [2032] USD 124.11 billion
CAGR (%) 11.41%

Biopharmaceuticals contract manufacturing has become a strategic pillar for drug developers seeking scalable capacity, specialized technical expertise, and compliant production across biologics, vaccines, biosimilars, cell therapies, gene therapies, and advanced protein-based medicines. As biologic pipelines expand and product modalities become more complex, outsourcing partners are increasingly involved from cell line development and process optimization through clinical supply, commercial manufacturing, fill-finish, packaging, analytical testing, and regulatory support. The sector is shaped by strict current good manufacturing practice requirements, rising adoption of single-use bioprocessing, stronger quality-by-design expectations, and the need for resilient global supply chains. Verified regulatory and public health priorities consistently point to the same imperatives: validated processes, robust contamination control, traceable raw materials, reliable cold-chain handling, and inspection-ready quality systems. For industry leaders, competitive advantage now rests on flexible manufacturing networks, digital process control, rapid technology transfer, and the ability to support both high-volume biologics and small-batch personalized therapies without compromising quality, traceability, or regulatory readiness.

Transformative Shifts Reshaping the Outsourcing Landscape

The biopharmaceuticals contract manufacturing landscape is undergoing structural change as demand shifts from conventional biologics toward more diverse and technically demanding modalities. Manufacturers are expanding capabilities in mammalian cell culture, microbial fermentation, high-potency biologics handling, viral vector production, mRNA-related workflows, aseptic fill-finish, and cold-chain-enabled distribution. Single-use systems are reducing changeover time and cross-contamination risk, while modular facilities are improving responsiveness for clinical and commercial programs. Regulatory authorities continue to emphasize data integrity, process validation, environmental monitoring, sterile assurance, and supply chain transparency, pushing contract manufacturers to strengthen digital quality systems and end-to-end documentation. At the same time, geopolitical uncertainty, pandemic-era lessons, medicine security policies, and regional biomanufacturing incentives are encouraging nearshoring, dual sourcing, and localized production strategies. The result is a more distributed, technology-intensive outsourcing ecosystem where speed, compliance, flexibility, and scientific depth are as important as production capacity.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing biopharmaceuticals contract manufacturing by improving process understanding, operational efficiency, quality oversight, and decision-making. AI-enabled analytics can support cell culture optimization, media formulation assessment, deviation detection, predictive maintenance, batch performance modeling, and real-time release strategies when combined with validated data governance frameworks. Machine learning tools are also helping analyze large volumes of process analytical technology data, environmental monitoring records, and quality control outputs to identify patterns that may not be visible through conventional review. In manufacturing operations, AI can contribute to scheduling optimization, capacity planning, raw material risk assessment, and automated documentation workflows. However, adoption must remain aligned with regulatory expectations for validation, explainability, cybersecurity, audit trails, and human oversight, including principles reflected in global good manufacturing practice and computerized systems guidance. The cumulative impact of AI is not the replacement of scientific and quality expertise but the elevation of process control, faster root-cause analysis, reduced operational variability, and stronger readiness for increasingly complex biologic production models.

Key Regional Insights in Contract Biomanufacturing

Asia-Pacific is strengthening its role in biopharmaceuticals contract manufacturing through expanding biologics infrastructure, government support for local pharmaceutical production, and growing clinical development activity across China, India, Japan, South Korea, Australia, and Southeast Asia. The region benefits from a large skilled scientific workforce, improving regulatory maturity, and rising investment in biosimilars, vaccines, cell therapy, sterile manufacturing, and technology transfer. Europe continues to be a leading center for high-quality biologics manufacturing, supported by mature regulatory oversight, specialized technical talent, and strong capabilities in aseptic processing, biosimilars, vaccines, and advanced therapies across major EU economies and the United Kingdom. North America remains a critical hub due to its advanced biopharma innovation base, established regulatory framework, deep clinical pipeline, and demand for high-compliance commercial biologics production, particularly in the United States and Canada. Latin America is advancing gradually as governments and health systems prioritize vaccine security, local biologics availability, and technology transfer, with Brazil and Mexico playing central roles in regional pharmaceutical manufacturing. Africa is at an earlier stage but is gaining policy attention due to vaccine manufacturing priorities, public health security objectives, and regional efforts to strengthen pharmaceutical self-sufficiency, creating long-term opportunities for workforce development, regulatory capacity building, and compliant local production. The Middle East is increasing biomanufacturing relevance through healthcare diversification initiatives, life sciences industrialization, and demand for regional supply resilience, particularly in Gulf economies where pharmaceutical localization and hospital system modernization are becoming strategic priorities.

Key Group Insights for Manufacturing Strategies

NATO member countries, while not a commercial bloc, represent a strategically significant network for supply chain resilience, biosecurity preparedness, and healthcare infrastructure coordination, reinforcing interest in secure manufacturing capacity, redundant supply sources, and reliable access to critical biologic medicines. G7 countries continue to anchor high-value contract manufacturing demand through strong innovation ecosystems, rigorous quality expectations, advanced regulatory agencies, and concentration of originator biologics, vaccines, and advanced therapy development. BRICS countries are central to global manufacturing resilience because they combine large patient populations, expanding domestic pharmaceutical industries, growing biologics pipelines, and policy support for local production, biosimilars, and technology transfer. The European Union remains highly influential due to its harmonized regulatory system, strong pharmacovigilance framework, advanced biomanufacturing workforce, and established demand for biosimilars, sterile biologics, and advanced therapy production. ASEAN is emerging as an important group for biopharmaceuticals contract manufacturing as member economies expand healthcare access, attract pharmaceutical investment, and improve regulatory cooperation for biologics and vaccines. The GCC is prioritizing life sciences localization as part of broader economic diversification, with emphasis on pharmaceutical security, hospital demand, cold-chain infrastructure, and strategic manufacturing partnerships.

Key Country Insights Across Leading Markets

China has rapidly expanded biologics and cell therapy manufacturing capability, supported by domestic innovation, regulatory modernization, and growing demand for outsourced development and manufacturing services. The United States leads demand for sophisticated biopharmaceuticals contract manufacturing due to its extensive biologics pipeline, advanced regulatory environment, and concentration of clinical-stage and commercial drug development. Japan maintains strength in high-quality biologics manufacturing, regulatory discipline, and specialty therapeutics, while India is a major force in biosimilars, vaccines, process development, and cost-efficient pharmaceutical production with increasing emphasis on global quality standards. Germany is recognized for high-quality pharmaceutical engineering, automation, sterile processing, and biologics production capabilities, while the United Kingdom continues to be important for advanced therapies, biologics research, clinical manufacturing expertise, and translational science infrastructure. Australia supports clinical biomanufacturing, early-stage development, and regional research collaboration, and France contributes through strong vaccine, sterile manufacturing, and life sciences infrastructure. South Korea has become a major Asia-Pacific biomanufacturing hub, with strong expertise in large-scale biologics production, biosimilars, and advanced facility execution. Italy and Spain both play meaningful roles in European sterile production, fill-finish, and pharmaceutical manufacturing services. Canada supports the ecosystem through investments in biologics, vaccine capacity, and life sciences innovation, while Russia's biopharmaceutical manufacturing landscape is shaped by domestic supply priorities and localization policies. Brazil remains Latin America's most prominent biologics manufacturing market, supported by public health programs, technology transfer initiatives, and biosimilar interest, while Mexico is gaining relevance as a nearshoring destination for pharmaceutical supply chain support, packaging, and regional healthcare demand.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturing flexibility, regulatory readiness, and supply chain resilience as core strategic imperatives. Contract manufacturing organizations and biopharma sponsors should invest in modular capacity, single-use technologies, advanced analytics, validated digital quality systems, and robust contamination control strategies. Technology transfer should be treated as a disciplined, data-driven process supported by standardized documentation, defined process parameters, method comparability, and early alignment between development and manufacturing teams. Leaders should also diversify critical raw material sources, qualify secondary suppliers, and strengthen cold chain and sterile logistics planning for sensitive biologics and advanced therapies. AI and automation should be deployed selectively in areas where data integrity, validation, auditability, and cybersecurity can be ensured. Workforce development is equally important, particularly in aseptic processing, bioprocess engineering, quality assurance, regulatory affairs, analytical testing, and advanced therapy manufacturing. Strategic partnerships should be evaluated not only on cost but also on technical capability, inspection readiness, quality culture, scalability, lifecycle support, and ability to move programs from clinical batches to commercial supply.

Research Methodology for Evidence-Based Insights

This executive summary is developed through a structured secondary research approach focused on verified industry, regulatory, scientific, and public policy sources. The methodology emphasizes triangulation of information from regulatory authority guidance, public health agency publications, peer-reviewed scientific literature, clinical development trends, manufacturing technology documentation, trade policy updates, and official government initiatives related to biologics and pharmaceutical production. Insights are assessed through qualitative validation across multiple credible sources to identify consistent patterns in technology adoption, regional manufacturing development, regulatory expectations, outsourcing strategies, and supply chain priorities. Particular attention is given to good manufacturing practice requirements, data integrity principles, biologics quality guidance, sterile manufacturing expectations, vaccine security initiatives, and advanced therapy production considerations. The analysis excludes market sizing, revenue estimation, market share calculation, and forecasting to maintain focus on evidence-based strategic interpretation. The research framework prioritizes data integrity, source credibility, current regulatory relevance, and practical applicability for stakeholders operating in biopharmaceuticals contract manufacturing.

Conclusion: Strategic Outlook for Contract Manufacturing

Biopharmaceuticals contract manufacturing is moving from a capacity outsourcing model toward a strategic partnership model defined by scientific specialization, regulatory excellence, digital maturity, and global supply resilience. As biologic modalities diversify and manufacturing requirements become more complex, success will depend on the ability to combine flexible production platforms with rigorous quality systems, validated digital tools, and responsive technology transfer. Regionalization, AI-enabled process intelligence, single-use bioprocessing, advanced therapy manufacturing, and stronger supply assurance are reshaping how sponsors select partners and how manufacturers design future-ready operations. Organizations that invest in compliant innovation, skilled talent, resilient supplier networks, transparent quality governance, and inspection-ready execution will be best positioned to support the next generation of biologics, biosimilars, vaccines, and personalized medicines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biopharmaceuticals Contract Manufacturing Market, by Service Type

  • 7.1. Introduction
  • 7.2. Analytical & Quality Control Testing
  • 7.3. Biologics Manufacturing Service
  • 7.4. Process Development & Optimization

8. Biopharmaceuticals Contract Manufacturing Market, by Product Type

  • 8.1. Introduction
  • 8.2. Cell And Gene Therapy
    • 8.2.1. CAR T Therapy
    • 8.2.2. Gene Editing Therapy
  • 8.3. Monoclonal Antibodies
  • 8.4. Recombinant Proteins
    • 8.4.1. Enzymes
    • 8.4.2. Hormones
  • 8.5. Vaccines
    • 8.5.1. mRNA Vaccines
    • 8.5.2. Protein Subunit Vaccines
    • 8.5.3. Viral Vector Vaccines

9. Biopharmaceuticals Contract Manufacturing Market, by Production Stage

  • 9.1. Introduction
  • 9.2. Clinical
    • 9.2.1. Phase I
    • 9.2.2. Phase II
    • 9.2.3. Phase III
  • 9.3. Commercial

10. Biopharmaceuticals Contract Manufacturing Market, by Organisation Size

  • 10.1. Introduction
  • 10.2. Large Organisation
  • 10.3. Small & Medium Organisation

11. Biopharmaceuticals Contract Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. Autoimmune Disorders
  • 11.3. Cardiovascular
  • 11.4. Infectious Diseases
    • 11.4.1. Bacterial
    • 11.4.2. Parasitic
    • 11.4.3. Viral
  • 11.5. Neurology
  • 11.6. Oncology

12. Biopharmaceuticals Contract Manufacturing Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Biopharmaceuticals Contract Manufacturing Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Biopharmaceuticals Contract Manufacturing Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Aenova Holding GmbH
  • 16.3. AGC Biologics
  • 16.4. Ajinomoto Co., Inc.
  • 16.5. Binex Co., Ltd.
  • 16.6. BioVectra Inc.
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. BSP Pharmaceuticals S.p.A.
  • 16.9. Cambrex Corporation
  • 16.10. Catalent, Inc.
  • 16.11. CordenPharma International GmbH
  • 16.12. Cytovance Biologics, Inc.
  • 16.13. Emergent BioSolutions Inc.
  • 16.14. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 16.15. GenScript Biotech Corporation
  • 16.16. IDT Biologika GmbH
  • 16.17. Jubilant Pharmova Limited
  • 16.18. KBI Biopharma, Inc.
  • 16.19. Lonza Group AG
  • 16.20. Piramal Pharma Limited
  • 16.21. ProBioGen AG
  • 16.22. Recipharm AB
  • 16.23. Rentschler Biopharma SE
  • 16.24. Samsung Biologics Co., Ltd.
  • 16.25. Siegfried Holding AG
  • 16.26. ST Pharm Co., Ltd.
  • 16.27. Thermo Fisher Scientific Inc.
  • 16.28. ThermoGenesis Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANALYTICAL & QUALITY CONTROL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALYTICAL & QUALITY CONTROL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALYTICAL & QUALITY CONTROL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MANUFACTURING SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MANUFACTURING SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MANUFACTURING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROCESS DEVELOPMENT & OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROCESS DEVELOPMENT & OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROCESS DEVELOPMENT & OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAR T THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAR T THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAR T THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HORMONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HORMONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMMERCIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMMERCIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMMERCIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LARGE ORGANISATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LARGE ORGANISATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LARGE ORGANISATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SMALL & MEDIUM ORGANISATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SMALL & MEDIUM ORGANISATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SMALL & MEDIUM ORGANISATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 168. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 169. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 171. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 257. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 258. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 259. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 260. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 271. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 296. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 301. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 302. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 303. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 304. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 307. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-20